10th European AIDS Conference/EACS, Dublin, November 2005
1 Comparison of resistance profiles between patients starting nevirapine and efavirenz in EuroSIDA. W Bannister, L Ruiz, B Ledergerber, A Cozzi-Lepri, O Kirk, S Staszewski,
C Loveday, B Clotet, A Phillips, J Lundgren for the EuroSIDA study group.
2 Evolution of drug resistance in HIV infected patients remaining on a virologically failing cART regimen. A Cozzi-Lepri, AN Phillips, L Ruiz, B Clotet, C Loveday, J Kjaer,
N Clumeck, L Viksna, F Antunes, L Machala and JD Lundgren.
1 Use of antimycotic therapy is an independent risk factor for HIV-disease progression among patients with a CD4 count above 200/µL in the era of combination antiretroviral therapy . D Podlekareva, A Mocroft, P Reiss, P Aldins, C Katlama, B Ledergerber, HJ Stellbrink, AD Monforte, O Kirk, JD Lundgren
Abstract PS 2/1
2 Is there an association between the endpoints in trials of virological efficacy and clinical long-term prognosis? O Kirk, A Mocroft, P Reiss, B Ledergerber, B Knysz, G Fätkenheuer, S Chaplinskas, JM Gatell, A Phillips, JD Lundgren for the EuroSIDA Study Group
Abstract PS 3/4
3 Clinical progression according to HIV drug resistance accumulated on antiretroviral therapy in EuroSIDA. A Cozzi-Lepri, A Phillips, A Mocroft, O Kirk, L Ruiz and JD Lundgren.
Abstract PS 6/4
4 Is there evidence for an increase in the death rate from liver-related diseade in patients with HIV? The EuroSIDA study. JD Lundgren, A Mocroft, V Soriano, J ROchstroh, P Reiss, O Kirk, S de Wit, JM Gatell, B Clotet, A Phillips
Abstract PS 7/2
12th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005
1 Risk of AIDS and death at given HIV-RNA and CD4 count level, according to specific antiretroviral drugs in the CART regimen. C Holkmann-Olsen, J Gatell, B Ledergerber, C Katlama, N Friis-Møller, J Weber, A Horban, S Staszewski, J Lundgren, A Phillips, and EuroSIDA
Poster #601(78 KB)
2 HIV-1 subtypes and virological response to HAART in Europe. W Bannister, L Ruiz, C Loveday, S Vella, K Zilmer, D Podlekareva, B Knysz, A Phillips, J Lundgren, A Mocroft and the EuroSIDA study group
Poster #598(157 KB)
3 Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on virological response to therapy. A Cozzi-Lepri, L Ruiz, C Loveday, A Phillips, B Clotet, P Reiss, J Lundgren, and EuroSIDA Study Group
Poster #708(113 KB)
4 A Comparison of Risk of Treatment Limiting Adverse Events in HCV-co-infected vs Non-co-infected persons with HIV in EuroSIDA. JD Lundgren, J Rockstroh, V Soriano, B Ledergerber, O Kirk, E Vinogradova, P Reiss, C Katlama, A Blaxhult, A Mocroft, and EuroSIDA Study Group
Poster #946(137 KB)